WASHINGTON, D.C.—Womble Bond Dickinson attorney Daniel Orr will take part in a panel discussion titled “Regulatory and IP Issues for Immunotherapies Including CAR-T and Antibody Technologies.”
The panel discussion is part of the American Intellectual Property Law Association Annual Meeting and takes place Friday, October 26 at the Marriott Wardman Park Hotel in Washington, D.C. The 2018 AIPLA Annual Meeting is a three-day conference for lawyers in private and corporate practice, in government service, and in the academic community, as well as patent agents and other IP law professionals.
Dan will speak concerning intellectual property issues that arise in FDA’s review of therapeutic biologics and biosimilars. Other members of the panel will include Daniel Lev of Intellia Therapeutics, Carla Mouta-Bellum of Arrigo, Lee, Guttman & Mouta-Bellum, LLP, and Laura Smalley of Harris Beach PLLC. More of the conference agenda can be seen here .
Daniel Orr is a Partner in the Washington, D.C. office of Womble Bond Dickinson. He advises clients concerning regulatory and patent issues in the pharmaceutical, biotech, and medical device sectors.
Before joining Womble Bond Dickinson in January 2018, Dan was a Regulatory Counsel in FDA’s Center for Drug Evaluation & Research where he solved regulatory problems in a portfolio of drugs and biologics with combined annual sales of more than $37 billion. Dan was the Regulatory Counsel assigned to three of the twelve biosimilars that FDA has approved to date, and developed patent policy for biological products. He also served on the CDER Exclusivity Board and was the subject-matter expert concerning reference product exclusivity for biological products.